Drug Approval | November 10, 2025
Glenmark secures China approval for Ryaltris
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
The platform is being introduced to expand access to treatments for people living with chronic conditions
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
A triple-action Formula for comprehensive respiratory relief
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Subscribe To Our Newsletter & Stay Updated
